These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 35316844)

  • 21. The role of talimogene laherparepvec (T-VEC) in the age of checkpoint inhibitors.
    Andtbacka RH
    Clin Adv Hematol Oncol; 2016 Aug; 14(8):576-9. PubMed ID: 27487099
    [No Abstract]   [Full Text] [Related]  

  • 22. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
    Garnock-Jones KP
    BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic virotherapy, alone or in combination with immune checkpoint inhibitors, for advanced melanoma: A systematic review and meta-analysis.
    Zou P; Tang R; Luo M
    Int Immunopharmacol; 2020 Jan; 78():106050. PubMed ID: 31812724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Live viruses to treat cancer.
    Donnelly O; Harrington K; Melcher A; Pandha H
    J R Soc Med; 2013 Aug; 106(8):310-4. PubMed ID: 23824333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
    Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
    Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status.
    Zhang Y; Liu Z
    Curr Pharm Des; 2019; 25(40):4251-4263. PubMed ID: 31682207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
    Hao M; Huang C; Xia N
    Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
    Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
    Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
    Dummer R; Hoeller C; Gruter IP; Michielin O
    Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncolytic viruses for cancer immunotherapy.
    Hemminki O; Dos Santos JM; Hemminki A
    J Hematol Oncol; 2020 Jun; 13(1):84. PubMed ID: 32600470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic virus therapy in advanced melanoma.
    Gourd E
    Lancet Oncol; 2017 Nov; 18(11):e649. PubMed ID: 29033197
    [No Abstract]   [Full Text] [Related]  

  • 32. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
    Ilett E; Kottke T; Thompson J; Rajani K; Zaidi S; Evgin L; Coffey M; Ralph C; Diaz R; Pandha H; Harrington K; Selby P; Bram R; Melcher A; Vile R
    Gene Ther; 2017 Jan; 24(1):21-30. PubMed ID: 27779616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune based therapy for melanoma.
    Ancuceanu R; Neagu M
    Indian J Med Res; 2016 Feb; 143(2):135-44. PubMed ID: 27121512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma.
    Zhu W; Lv J; Xie X; Tian C; Liu J; Zhou H; Sun C; Li J; Hu Z; Li X
    Immunol Lett; 2022 Jan; 241():15-22. PubMed ID: 34774916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Herpes simplex virus oncolytic vaccine therapy in melanoma.
    Sivendran S; Pan M; Kaufman HL; Saenger Y
    Expert Opin Biol Ther; 2010 Jul; 10(7):1145-53. PubMed ID: 20515292
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?
    Cejalvo JM; Falato C; Villanueva L; Tolosa P; González X; Pascal M; Canes J; Gavilá J; Manso L; Pascual T; Prat A; Salvador F
    Cancer Treat Rev; 2022 May; 106():102392. PubMed ID: 35436729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncology's Trojan Horse: Using Viruses to Battle Cancer.
    Mavani HJ; Wick JY
    Consult Pharm; 2016 Dec; 31(12):676-684. PubMed ID: 28074746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intratumoral Approaches for the Treatment of Melanoma.
    Bommareddy PK; Silk AW; Kaufman HL
    Cancer J; 2017; 23(1):40-47. PubMed ID: 28114253
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The treatment of advanced melanoma: a review of systemic and local therapies in combination with immune checkpoint inhibitors in phase 1 and 2 clinical trials.
    DePalo DK; Tarhini A; Zager JS
    Expert Opin Investig Drugs; 2022 Jan; 31(1):95-104. PubMed ID: 34996314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Oncolytic Properties of a Mumps Virus Vaccine Strain in Human Melanoma Cell Lines].
    Ammour YI; Ryabaya OO; Milovanova AV; Sidorov AV; Shohin IE; Zverev VV; Nasedkina TV
    Mol Biol (Mosk); 2018; 52(4):659-666. PubMed ID: 30113031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.